SEC Form 20-F filed by IM Cannabis Corp.
$IMCC
Medicinal Chemicals and Botanical Products
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/5/2021 | $8.00 | Buy | ROTH Capital |
| 7/14/2021 | Buy | Desjardins | |
| 7/14/2021 | $10.50 | Buy | Desjardins |
TORONTO and GLIL YAM, Israel, May 28, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announces that it has applied for a voluntary delisting of its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). The delisting from the CSE will not affect the Company's listing on NASDAQ and its Shares will continue trading on the NASDAQ under the symbol "IMCC". The Company is entertaining potential transactions that, if completed while the Company is listed on the CSE, would require the Company to incur unnecessary burdensome costs, approvals and delay. The Company believes that the trading volu
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel, May 27, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce the following corporate updates. Meeting Results Further to its press releases dated Aprill 11, 2025 (the "April 11 Release") and May 7, 2025 (the "May 7 Release"), the Company is pleased to announce results of its annual general and special meeting, held on Friday, May 23, 2025 (the "Meeting"
IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress TORONTO and GLIL YAM, Israel, May 15, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated. IMC also announces the intention to complete a non-brokered private placement of secured debentures. Q1 2025 Financial Highlights Net profit of $175K94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gr
ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00
Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy
Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of
TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023. This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin
Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
6-K - IM Cannabis Corp. (0001792030) (Filer)
IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress TORONTO and GLIL YAM, Israel, May 15, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated. IMC also announces the intention to complete a non-brokered private placement of secured debentures. Q1 2025 Financial Highlights Net profit of $175K94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gr
TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the
Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage
SC 13G - IM Cannabis Corp. (0001792030) (Subject)
SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)
SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)